The PI3K-AKT pathway has pleiotropic effects, and its inhibition has long been of interest in the management of prostate cancer, where a compensatory increase in PI3K signaling has been reported following Androgen Receptor (AR) blockade. Prostate cancer cells can also bypass AR blockade through induction of other hormone receptors, in particular the glucocorticoid receptor (GR). Here we demonstrate that AKT inhibition significantly decreases cell proliferation through both cytostatic and cytotoxic effects. The cytotoxic effect is enhanced by AR inhibition and is most pronounced in models that induce compensatory GR expression. AKT inhibition increases canonical AR activity and remodels the chromatin landscape, decreasing enhancer interaction at the GR gene (NR3C1) locus. Importantly, it blocks induction of GR expression and activity following AR blockade. This is confirmed in multiple in vivo models, where AKT inhibition of established xenografts leads to increased canonical AR activity, decreased GR expression, and marked anti-tumor activity. Overall, our results demonstrate that inhibition of the PI3K/AKT pathway can block GR activity and overcome GR-mediated resistance to AR-targeted therapy.
INTRODUCTION
Suppression of androgen synthesis and androgen receptor (AR) activity via chemical castration and/or an AR antagonist is the mainstay of systemic prostate cancer therapy 1 . While almost all patients have an initial favorable response, inevitably resistance develops and patients relapse with progressive disease 2, 3 . Multiple mechanisms can promote resistance, including reactivation of AR through amplification of the AR gene and/or an enhancer, mutation, or expression of AR variants [4] [5] [6] [7] . Expression of alternate hormone receptors with overlapping downstream targets can also promote resistance. Recent preclinical and clinical studies suggest the glucocorticoid receptor (GR) is the primary hormone receptor whose activity confers resistance to AR-targeted therapy 8, 9 . Resistance to AR-targeted therapy through induction of GR expression is the basis for multiple clinical trials combining inhibition of GR with enzalutamide (NCT03674814, NCT02012296, NCT03437941).
There is also cross-talk between androgen signaling and PI3K/AKT pathway activation.
The PI3K/AKT pathway is a complex, branching and looping signaling pathway that is involved in survival, proliferation, metabolism, and growth pathways 10 . In prostate cancer, castration or AR antagonism has been shown to increase phosphorylation of AKT and downstream targets, and loss of PTEN, a negative regulator of the PI3K/AKT pathway, correlates with decreased AR activity 11 . Ipatasertib is a potent, pan-AKT inhibitor that binds AKT in an ATP-competitive manner, consequently disrupting its effect on downstream targets 12, 13 . It has activity in combination with the CYP17A1 inhibitor abiraterone plus prednisone in metastatic castrateresistant prostate cancer (mCRPC) 14 . Given encouraging preliminary data, there are several ongoing clinical trials assessing the therapeutic benefit of ipatasertib in combination with other antineoplastic agents, including in prostate cancer [15] [16] [17] ; however, the optimal setting for AKT inhibition is unknown.
Here we demonstrate that inhibition of AKT has a cytostatic effect on prostate cancer cells despite increasing AR activity and is cytotoxic in combination with AR antagonism. Moreover, among the effects of PI3K/AKT pathway inhibitors, they block the induction of GR seen in response to AR blockade, which is associated with remodeling of the chromatin landscape and effects on transcriptional regulation. In in vivo models of established tumors, AKT inhibition enhances canonical AR activity, blocks GR expression, and demonstrates marked antitumor activity.
MATERIALS AND METHODS

Cell Lines and Reagents
LNCaP and C4-2 were purchased from ATCC (ATCC.com). LAPC4 and LREX were provided by Dr. Sawyers, Memorial Sloan Kettering Cancer Center. LNCaP, C4-2, 22Rv1 and LREX cells were cultured in RPMI1640+GlutaMAX (Gibco, Life Technologies), 10% FBS (Gibco, Life Technologies), 1% Penicillin/Streptomycin (Corning). For androgen deprivation in vitro studies, 10% charcoal stripped serum (CSS) (Gibco, Life Technologies) was used in place of 10% FBS.
All cell lines were tested for mycoplasma contamination (PCR Mycoplasma Detection; primer sequence in Supplementary Table 1 ) every 6 months. LuCaP PDX models (provided by Dr. E.
Corey and Dr. R. Vessella, Washington University) were grown in organoid culture in advanced DMEM/F12 media with supplements, as previously published 18 . For in vitro studies, ipatasertib (Chemietek) and enzalutamide (Selleckchem) were dissolved in DMSO. CellTitre Glo Assay (Promega) was used to assess cell viability. For in vivo studies, ipatasertib (Division of Cancer Treatment and Diagnosis, NCI Developmental Therapeutics Program) and Enzalutamide (DCTD, NCI DTP) were dissolved in 1:1 of labrasol (Gattefosse) to PEG400 (Sigma).
Western Blot Analysis
Cell lines and xenograft tumors collected at the end of treatment (EOT) time point were lysed using standard protocol. Lysates generated were used to perform immunoblot as previously described 19 . Primary antibodies are diluted 1:1000 and from Santa Cruz (AR) or Cell Signaling Technology (AKT, p-AKT(Thr308), p-AKT (Ser483), GR, P70S6K, p-P70S6K, 4EBP1, p-4EBP1, and GAPDH). Secondary antibodies against rabbit (1:5000, EMD Millipore) or mouse (1:5000; EMD Millipore) were used followed by band detection using Amersham ECL Prime western blotting detection reagent (GE Lifesciences) per manufacturer's instructions and visualized using ChemiDoc Touch Imaging system (Bio-Rad). Quantitative measurements of western blot analysis were performed with ImageJ and GraphPad Prism8 software.
Quantitative RT-PCR (qRT-PCR) Analysis
mRNA extracts from cell lines and xenograft collected post EOT time points were used to perform qRT-PCR as previously described 19 for detection of KLK3, NKX3-1, and NR3C1 (Supplemental Table 1 ). PCR was performed on a StepOnePlus Real-Time PCR System (Applied Biosystems).
PCR arrays were used to evaluate expression of a panel of 84 genes putatively regulated by GR (PAHS-154ZA) or by AR (PAHS-142ZA) (Qiagen). For the AR array, seven genes were removed from further analysis because their expression was increased by enzalutamide.
RNA-Seq Analysis
RNA was extracted, quantified and profiled for quality using a Bioanalyzer (Agilent https://github.com/GryderArt/VisualizeRNAseq/).
ChIP-Seq Analysis
Chromatin was isolated from cells using ChIP-IT High Sensitivity Kit (Active Motif) Chromatin folding was inferred from analysis of public HiC data 20 (https://aidenlab.org/juicebox/).
Gene Overexpression and Knockdown Assays
For GR (NR3C1) overexpression transfections, cells were transfected with 1-2µg NR3C1(Myc- 
Statistics
Statistical analysis was performed using GraphPad prism (version 7.0a). In brief, data analyses are expressed as the mean + standard error of mean (SEM) unless otherwise stated. Statistical significance where appropriate was evaluated using a two-tailed student t test when comparing two groups, or by one-way analysis of variance (ANOVA), using the student-Newman Keuls post-
RESULTS
The pan-AKT inhibitor ipatasertib decreases cell viability in an enzalutamide-resistant
prostate cancer cell line. The PI3K/AKT signaling pathway is hyperactive in 50-60% of advanced prostate cancer 22 , and the AKT inhibitor ipatasertib is currently in clinical development.
We sought to determine the effects of ipatasertib (100nM) or enzalutamide in models representing castrate resistant prostate cancer (CRPC). We utilized 22RV1, which is known to harbor full length AR and ARV7, C4-2 (LNCAP/AR derived CRPC) and LREX (LNCAP/AR Resistant to Enzalutamide). Cells were exposed to enzalutamide (2 µM) or ipatasertib (100nM) in the setting of androgen deprivation. Response to enzalutamide was modest in 22Rv1 and C4-2 cell lines, as was response to ipatasertib ( Fig. 1a, 1 st and 2 nd panel). In contrast, LREX, which is poised to upregulate GR expression to achieve enzalutamide resistance 8 , was confirmed to be completely resistant to enzalutamide but had a marked response to ipatasertib ( Fig. 1a, 3 
rd panel). Consistent
with its mechanism of action, the effect of ipatasertib on cell viability correlated with inhibition of AKT signaling, which is manifest as an increase in AKT phosphorylation (due to its ability to protect against phosphatases) and decrease in phosphorylation of downstream targets ( Fig. 1b) .
To determine if ipatasertib would be of benefit in hormone sensitive prostate cancer (HSPC), we tested its effect alone vs. androgen withdrawal in the well-characterized HSPC cell lines LNCaP and LAPC4. Both models of HSPC were more sensitive to ipatasertib than to androgen withdrawal (Extended Data Fig. 1a ). Western blot analysis confirmed ipatasertib inhibited AKT signaling.( Fig. 1b ). Taken together, these results indicate heterogenous response to ipatasertib as monotherapy. Amongst all 3 CRPC models tested, ipatasertib was most active in the enzalutamide resistant CRPC (LREX) cells.
Extended Data
Ipatasertib induces cell cycle arrest as monotherapy and apoptosis in combination with
enzalutamide. The LREX cell line was derived from LNCaP/AR with in vivo selection for enzalutamide resistance 8, 23 . We evaluated response to enzalutamide and ipatasertib alone and in combination in a dose dependent manner for 48 hours. We confirmed that LREX cells were resistant to enzalutamide at 10uM, with no difference in cell viability compared to DMSO treated cells ( Fig. 2a) . However, we observed response to ipatasertib single agent in a dose dependent manner which was enhanced when combined with single dose enzalutamide ( Fig. 2a) . Similarly, in a time dependent manner (24hrs to 168hrs of treatment) using single dose ipatasertib (100nM) and Enzalutamide, we again observed no response to enzalutamide ( Fig. 2b) . LREX cells continue to be sensitive to ipatasertib over time, with approximately 50% growth suppression.
Combination of ipatasertib and enzalutamide led to almost complete growth suppression ( Fig. 2b) .
To determine the mode of cell death following ipatasertib alone or when combined with enzalutamide, we performed cell cycle analysis using propidium iodide (PI) after 24 hours of treatment. Single agent ipatasertib induced a G0/G1 cell cycle arrest (Fig. 2c) , and when combined with enzalutamide we found an increased subG1 population, indicative of apoptosis ( Fig. 2c) . We confirmed the apoptotic cell death using annexin V/PI staining of live cells. Indeed, we observed increased apoptosis in cells treated with both ipatasertib and enzalutamide compared to single agents ( Fig. 2d) . Taken together, our data suggest that ipatasertib halts cell growth primarily by inducing cell cycle arrest, and when combined with enzalutamide, it induces apoptotic cell death.
Inhibition of AKT blocks the induction of GR expression and activity through chromatin landscape reorganization. Induction of compensatory glucocorticoid receptor (GR) expression
has been reported in a subset of enzalutamide resistant CRPC patients as a mechanism of resistance to AR blockade 8 . Given the role of GR in enzalutamide resistance in LREX, we sought to determine the effect of AKT inhibition on GR. We examined expression of the GR protein in LREX cells by western blot analysis following AKT and AR inhibition for two days. LREX cells in androgen-deprived media induced GR protein expression, which ipatasertib completely inhibited ( Fig. 3a ). LREX exposed to enzalutamide induced even higher expression of GR, which was significantly decreased when also exposed to ipatasertib ( Fig. 3a) . LNCaP have also been shown to induce GR expression, though over longer-term androgen inhibition 24 . In LNCaP cells,
we observed an induction of GR expression after 7 days of exposure to enzalutamide, which is completely blocked by exposure to ipatasertib (Extended Data Fig. 2a ).
To determine if the decrease in GR expression correlates with GR activity, LREX cells were transfected with a luciferase reporter whose expression is driven by multiple copies of the GR response element. When these cells were exposed to 100 nM ipatasertib for 48 hours, luciferase production decreased significantly. Conversely, when these cells were exposed to enzalutamide, they had increased luciferase production ( Fig. 3b) . To evaluate GR activity in a more physiologic setting, we performed a PCR array using 84 putative GR-regulated genes. Confirming the luciferase assay finding, ipatasertib lead to decreased expression of a broad range of GR-regulated genes, indicating decreased GR activity ( Fig. 3c) .
LREX cells have a dynamic reprogramming system with enzalutamide, as these cells are poised to switch on GR for survival when faced with AR blockade. This dynamic on and off switch suggests there is an epigenetic influence on gene expression modulated via typical enhancers (TE) or super-enhancers (SE). Epigenetic processes such as histone modifications at cis-regulatory elements can affect gene transcription independent of their orientation or distance via enhancers 25 . H3K27ac has been established as an important mark of enhancers which distinguishes between active and inactive regions (active referring to a positive influence on the expression of proximal genes) 26 , hence, regions with deposits of H3K27ac are often associated with enhanced gene activity 26, 27 . We performed Chromatin Immunoprecipitation (ChIP) experiments for H3K27ac in the presence of DMSO, ipatasertib, enzalutamide or the combination of both ipatasertib and enzalutamide, with RNA-seq performed in parallel. First, we looked at global changes of H3K27ac binding across all treatment groups and observed a gradual switch in H3K27ac bound regions in ipatasertib treatment compared to control or enzalutamide and a complete flip in cells treated with ipatasertib and enzalutamide ( Fig. 3d) . When we ranked in order of binding change, the GR gene, NR3C1, ranked amongst the top genes to have decreased H3K27ac deposits ( Fig. 3e) . To ensure we searched the same cis-regulatory space available to NR3C1 in 3-dimensions, we used published HiC data 28 identifying chromatin interactions inside the nucleus and found clear boundaries (black lines, Fig. 3f ) of an insulated neighborhood in which active enhancers could directly influence NR3C1 29 . Interestingly, regions on the NR3C1 locus with enhancer deposition in the presence of enzalutamide or DMSO were completely eliminated with ipatasertib or combination of both ipatasertib and enzalutamide (Fig. 3f) . The epigenetic shutdown of NR3C1 expression was corroborated by RNA-seq and qRT-PCR (Extended Data Fig. 2b,c) . Taken together, these data suggest AKT inhibition deactivates GR through cis-regulatory elements at the NR3C1 locus that sense the depletion in PI3K-AKT signal.
To determine if inhibition of GR expression is specific to inhibition of AKT by ipatasertib or occurs with antagonism of other PI3K/AKT pathway members, we exposed LREX cells to the AKT inhibitor MK2206, the PI3K inhibitors taselisib or buparlisib, or the mTOR inhibitor everolimus in the setting of androgen deprivation. Stimulation of AR with the synthetic androgen R1881 led to a decrease in GR expression. In contrast, AR inhibition with enzalutamide increased GR expression. All four inhibitors of the PI3K/AKT pathway decreased GR expression similar to that of ipatasertib ( Fig. 3g) . Taken together, our results suggest PI3K/AKT inhibitors remodel the chromatin landscape to block the induction of GR expression at the transcript level and resensitize cells to enzalutamide.
Inhibition of GR is required for sensitivity to ipatasertib in the context of GR-dependent tumor growth. To confirm if re-sensitization of cells to enzalutamide by ipatasertib treatment was through inhibition of GR, we genetically knocked down NR3C1 in LREX cells using shRNA ( Fig. 4a,b) . We then treated two independent NR3C1-KD lines with enzalutamide. Our data demonstrated ~50% decrease in cell viability compared to the non-silencing (NS) control cells treated with enzalutamide ( Fig. 4c) , which phenocopies the effect seen when we treat cells with ipatasertib and enzalutamide.
Next, we sought to determine if decreased GR expression is required for sensitivity to ipatasertib.
We maintained GR expression in LREX and LNCaP cells by transfecting them with a GR-expression construct ( Fig. 4d and Extended Data Fig. 3a,b) . In both models, cells with exogeneous expression of GR demonstrate decreased sensitivity to ipatasertib (Fig 4e) . In contrast to LNCaP and LREX, the 22RV1 cell line has high NR3C1 mRNA and GR protein expression at the basal level and lacks further induction of GR expression following AR inhibition (Extended Data Fig. 3c, right panel) 24 . GR protein level is maintained in the presence of ipatasertib, and the cell line is minimally sensitive to ipatasertib (Extended Data Fig. 3c, left panel) . This observation suggests that the effect of ipatasertib on GR expression and cell viability is enhanced when GR is induced by AR inhibition, but not when there is constitutive high expression. Overall, our data suggest that AKT inhibition blocks the induction of GR, reducing cell viability and increasing sensitivity to AR blockade.
Impact of AKT inhibition on GR expression is modulated by AR.
We have demonstrated blockade of GR expression at the protein and transcript level using several PI3K/AKT pathway inhibitors, including ipatasertib ( Fig. 3g) . Interestingly, exogenous androgen (R1881) also suppressed NR3C1 expression, whereas NR3C1 expression was increased in the presence of enzalutamide. PI3K-AKT pathway signaling was previously shown to suppress AR activity, and AR is thought to negatively regulate transcription of NR3C1 9 . To determine if AKT inhibition suppresses GR expression and activity through AR-mediated regulation of transcription, we determined the effect of ipatasertib on canonical AR activity. Gene set enrichments analysis (GSEA) was performed using RNA-seq to identify gene sets that were significantly enriched or depleted with each treatment condition. We found among MSigDB Hallmark gene sets, the most upregulated in any condition was Androgen signaling following exposure to ipatasertib (Fig. 5a,b and Extended Data Fig. 4) . We further examined the expression of a panel of AR-regulated genes following exposure to ipatasertib or enzalutamide. Whereas enzalutamide decreased the expression of AR-regulated genes, ipatasertib caused a mixed response where, on average, the expression of AR target genes was increased (Extended Data Fig. 5a ). Additionally, we examined AR activity using a luciferase reporter driven by tandem AR response elements. While ipatasertib alone drove similar expression to control, enzalutamide markedly decreased luciferase expression, which was reversed by adding in ipatasertib (Extended Data Fig. 5b) .
To more broadly examine the effect of ipatasertib exposure on transcription activity, we looked at transcription factor motif enrichment. Motif analysis in H3K27ac-decorated chromatin identified enrichment in samples treated with ipatasertib, both alone and in combination with enzalutamide, of transcription factor sequences recognized by the AR (Fig. 5c) . We observed substantial deposition of H3K27ac at several canonical AR target loci, including the KLK3 super enhancer locus, which was increased by ipatasertib and decreased by enzalutamide (Fig 5d) . RNA-seq experiments performed in parallel indicate increased transcription of KLK3 and TMPRSS2 with ipatasertib treatment (Fig. 5e) .
To further evaluate the direct effect of AR on GR expression at the transcript level, we genetically knocked down the AR gene in LREX cells. We selected two of four target sequences that produced >70% knockdown for our experiments (Fig. 5f) . We demonstrate that in both AR-knockdown models, there was an increased in GR expression compared to the non-silencing control, confirming that AR activity directly influences GR expression ( Fig. 5g) . Taken together, these data indicate AKT inhibition both activates canonical AR targets and blocks GR induction through cis-regulatory elements that sense the depletion in PI3K-AKT signal.
Combination AKT inhibition and androgen inhibition decreases tumor size across multiple xenograft models
To determine how ipatasertib would affect established tumors, either alone or in the setting of ARtargeted therapy, we measured the tumor volume of two independent PDX models treated with ipatasertib and/or castration. These models represent a range of AR activity and ARresponsiveness 21 . When tumors were well established (~500 mm 3 ), the mice were castrated, given ipatasertib by oral gavage daily (5days on; 2 days off), or both. In both models ipatasertib halted tumor growth as well as or better than castration (average relative change compared to pretreatment with ipatasertib, -0.3632 vs. control 0.6591; p=0.002) (Fig. 6a) . Moreover, castration and ipatasertib combined consistently led to decreases in tumor volume in each model (average relative change compared to pre-treatment in combination, -2.737 vs. control, ipatasertib and castration 0.4069; p=0.0004) (Fig. 6a) .
We additionally tested ipatasertib and AR inhibition in two models of CRPC. The LuCaP 136CR-N model was derived in vivo from the parental LuCaP 136 model grown in castrated mice. We also examined xenografts grown from the LREX cell line. Castrated mice harboring tumors from these CRPC models were exposed to ipatasertib, enzalutamide, or both. In both CRPC models, enzalutamide had little effect, with tumor growth rates similar to that of controls (average relative change compared to pre-treatment in enzalutamide, 0.5180 vs. control, 0.5844; p=0.99) (Fig. 6b) .
Ipatasertib, however, caused a dramatic slowing of tumor growth or a decrease in tumor volume (average relative change compared to pre-treatment with ipatasertib, -14.95 vs control and enzalutamide, p=0.0003). The combination of enzalutamide and ipatasertib showed similar results (average relative change compared to pre-treatment with combination, -23.15 vs control and enzalutamide p=0.0001) (Fig. 6b) . Thus, there is a consistent anti-tumor effect of AKT inhibition in diverse in vivo prostate cancer models, representing both hormone sensitive and resistant disease.
AKT inhibition enhances AR activity and decreases GR expression in vivo
Having demonstrated in cell line models that PI3K/AKT pathway inhibitors block GR expression, and that this regulation of GR expression is in part through increased AR activity, we sought to confirm these findings in mouse xenograft models. We took end of treatment tumors from experiments shown in Figure 6 and evaluated mRNA and/or protein of GR and AR-regulated genes. Similar to in vitro experiments, castration or enzalutamide led to a marked decrease of AR activity, as indicated by decreased expression of downstream genes KLK3 and NKX3-1, whereas ipatasertib caused increased expression of these genes (Fig. 7a,b,c,d) . Ipatasertib caused concomitant decrease in GR protein level, which was maintained or increased with castration ( Fig.   7e ). Similar results were seen in CRPC models treated with enzalutamide ( Fig. 7f) . These effects were maintained throughout treatment, as tumors were harvested after 2 or 4 weeks of therapy.
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DISCUSSION
The PI3K/AKT pathway is a complex signaling pathway that is involved in survival, proliferation, metabolism, and growth pathways. In the current study we show that inhibition of the PI3K/AKT signaling pathway can block GR expression that is induced as a resistance mechanism to AR-targeted therapy, both when combined with androgen deprivation or the AR antagonist enzalutamide. In multiple prostate cancer xenograft models representing a spectrum of AR-dependence, this leads to significant anti-tumor response. Blockade of GR expression is associated with reorganization of the chromatin landscape, induction of canonical AR activity, and decreased expression of the GR gene, NR3C1 (Fig. 7g) .
While multiple mechanisms can lead to resistance to AR-targeted therapy, one that has drawn particular interest is the induced expression of GR, leading to a new therapeutic strategy for a subset of prostate cancer patients. Interestingly, the upregulation of GR as compensatory hormone receptor signaling has also been reported in breast cancer and is associated with poor prognosis in triple-negative breast cancer 30, 31 . It is likely that diverse mechanisms can regulate GR expression in diverse prostate cancers subtypes. Indeed, 22Rv1 cells, which express constitutively high levels of GR that is not affected by AR inhibition nor ipatasertib, are relatively resistant to ipatasertib. Nevertheless, we demonstrate here that ipatasertib blocks the induction of GR expression across numerous models tested, both in vitro and in vivo, which is associated with ipatasertib sensitivity. In two engineered GR-overexpressing cells lines we show enforced GR expression reduces ipatasertib sensitivity, demonstrating the key role of GR expression and activity in response and resistance to AKT inhibition. To our knowledge, this is the first demonstration that PI3K/AKT pathway inhibition blocks GR expression in prostate cancer, leading to significant anti-tumor effect.
The strongest evidence to date for upregulation of GR is in response to enzalutamide for mCRPC 8, 9, 24, 32 . In advanced prostate cancer ipatasertib has been used in combination with abiraterone, which is given with prednisone, providing further rationale for blockade of GR contributing to anti-tumor effect. The importance of GR expression for development of castrate resistance in newly diagnosed metastatic disease in response to initial therapy, whether with ADT alone, ADT and docetaxel, or ADT and abiraterone/prednisone, has not been investigated. It is worth noting that we found marked anti-tumor effect with ipatasertib monotherapy and in combination with castration in multiple PDX models of HSPC. In some respects, high risk localized disease may have similar biology to metastatic HSPC. Upregulation of GR expression has been demonstrated in a subset of patients in both neoadjuvant enzalutamide and neoadjuvant abiraterone/prednisone trials in this setting 33, 34 , raising the question of whether adding a PI3K/AKT inhibitor could improve the outcomes for those with HSPC. One explanation for the prevalence of GR expression in these early phase studies, as opposed to well-characterized genomic alterations (e.g. AR enhancer amplification), is that development of resistance through selection of genomically altered subclones may require more time, and later stage disease, than induction of GR.
In our studies regulation of GR induction by the PI3K/AKT pathway is associated with remodeling of the chromatin landscape. It is likely there are additional important consequences of chromatin remodeling aside from regulation of GR expression and activity. The consistent effects on GR across diverse models, however, and the requirement for GR inhibition for maximal inhibitor sensitivity, suggest that the effect on the NR3C1 gene and GR activity may be crucial.
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The PI3K/AKT pathway has been demonstrated to have effects on the chromatin landscape in breast cancer, as well, another hormone receptor-regulated cancer 35 . The full consequences of AKT inhibition on chromatin remodeling in prostate cancer have yet to be elucidated.
Along with inhibition of GR, AKT inhibition induces an increase in canonical AR activity.
This seems counterintuitive, since many prostate cancer therapies are designed to inhibit AR
activity. Yet others have noted in tumor samples that high AR activity is associated with low cell proliferation 36 . It is not clear if this is the same mechanism behind responses induced by supraphysiologic testosterone in recent clinical trials 37, 38 . It may be that increased canonical activity is associated with decreased non-canonical activity. More extensive studies will be required to tease out the paradoxical mechanisms behind different levels of AR activity.
It has been suggested that PI3K/AKT targeted therapies might drive differentiation toward t-SCNC, as demonstrated with the LNCaP cell line 39 . In our data, however, a PDX model of small cell cancer (LuCaP 145.1) was particularly sensitive to AKT inhibition in 3D organoid culture (Extended Data Fig. 6 ). Another responsive model in vivo, LuCaP 136, represents aggressive variant prostate cancer due to loss of function of both PTEN and TP53 40 . Indeed, others have demonstrated that activated AKT and N-MYC combine to drive a neuroendocrine phenotype 41 , supporting the use of an AKT inhibitor for tumors with neuroendocrine features.
This study was focused on prostate cancer, for which induction of GR expression is a demonstrated mechanism of resistance for established therapies. PI3K-pathway inhibition in general, and AKT inhibition with ipatasertib in particular, have been and continue to be tested in a number of other solid tumors. In breast cancer, GR expression has been shown to play a role in resistance to taxanes, with apparently opposite effects in hormone receptor positive and hormone 23 receptor negative disease 30 . It is not known if ipatasertib blocks GR activity in breast cancer as it does in prostate cancer, or if that plays a role in the efficacy seen in a recent phase II study 16 .
The long history of PI3K/AKT pathway inhibitors for the treatment of prostate cancer and other solid tumors has translated to only modest success in the clinic. The pan-AKT inhibitor ipatasertib shows promise in combination with abiraterone plus prednisone for late stage prostate cancer. Our data demonstrate marked anti-tumor effect in models that upregulate GR to induce resistance. A better understanding of the clinical settings in which GR activity is most critical will help usher in a new target in the prostate cancer therapy armamentarium.
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